Trial Profile

An Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Injection in Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emfizatamab (Primary)
Indications Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Sichuan Baili Pharmaceutical

18 Dec 2024 Planned End Date changed from 1 Feb 2025 to 1 Dec 2025.
18 Dec 2024 Planned primary completion date changed from 1 Feb 2025 to 1 Jun 2025.
17 Mar 2023 Planned End Date changed from 1 Dec 2024 to 1 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com